Updating results

609 results

Sort: Relevance | Date

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

In development [GID-IPG10067] Expected publication date: TBC

Interventional procedures guidance In development

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Technology appraisal guidance In development

Selumetinib for treating differentiated thyroid cancer ID1079

In development [GID-TA10207] Expected publication date: TBC

Technology appraisal guidance In development

Talacotuzumab for untreated acute myeloid leukaemia [ID1262]

In development [GID-TA10249] Expected publication date: TBC

Technology appraisal guidance In development

NY-ESO-1 T-cells for treating synovial sarcoma ID1286

In development [GID-TA10205] Expected publication date: TBC

Technology appraisal guidance In development

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

In development [GID-TA10251] Expected publication date: TBC

Technology appraisal guidance In development

Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Technology appraisal guidance In development

Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297

In development [GID-TA10311] Expected publication date: TBC

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]

In development [GID-TA10317] Expected publication date: TBC

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

In development [GID-TA10510] Expected publication date: TBC

Technology appraisal guidance In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [ID1655]

In development [GID-TA10565] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Esketamine for treatment-resistant depression (ID1414)

In development [GID-TA10371] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

In development [GID-TA10623] Expected publication date: TBC

Technology appraisal guidance In development

Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]

In development [GID-TA10299] Expected publication date: 22 July 2020

Technology appraisal guidance In development

QAngio XA 3D/ QFR and CAAS vFFR imaging software for assessing the functional significance of coronary obstructions during invasive coronary angiography

In development [GID-DG10034] Expected publication date: 30 September 2020

Diagnostics guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm ID1556

In development [GID-TA10482] Expected publication date: 24 March 2021

Technology appraisal guidance In development

Acne Vulgaris: Management

In development [GID-NG10109] Expected publication date: 13 January 2021

NICE guideline In development

Minimally invasive radical hysterectomy for early stage cervical cancer

In development [GID-IPG10131] Expected publication date: 18 March 2020

Interventional procedures guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]

In development [GID-TAG430] Expected publication date: 28 October 2020

Technology appraisal guidance In development

Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Highly specialised technologies guidance In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Endo-Sponge for treating colorectal anastomotic leakage

In development [GID-MT539] Expected publication date: 01 September 2020

Medical technologies guidance In development

Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]

In development [GID-HST10027] Expected publication date: 11 November 2020

Highly specialised technologies guidance In development

Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)

In development [GID-TA10366] Expected publication date: TBC

Technology appraisal guidance In development

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

In development [GID-TA10385] Expected publication date: 27 January 2021

Technology appraisal guidance In development

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

In development [GID-TA10577] Expected publication date: 21 April 2021

Technology appraisal guidance In development

Magnetic resonance therapy for knee osteoarthritis

In development [GID-IPG10159] Expected publication date: TBC

Interventional procedures guidance In development

Endobronchial vagal nerve ablation for chronic obstructive pulmonary disease

In development [GID-IPG10160] Expected publication date: TBC

Interventional procedures guidance In development

Diabetes in pregnancy: management from preconception to the postnatal period

In development [GID-NG10158] Expected publication date: TBC

NICE guideline In development

Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)

In development [GID-IPG10161] Expected publication date: TBC

Interventional procedures guidance In development

Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

In development [GID-TA10459] Expected publication date: 08 April 2020

Technology appraisal guidance In development

Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s

In development [GID-NG10098] Expected publication date: 05 November 2020

NICE guideline In development

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

In development [GID-TA10566] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Dupilumab for treating severe asthma [ID1213]

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 19 August 2020

NICE guideline In development

Rehabilitation after traumatic injury

In development [GID-NG10105] Expected publication date: 04 August 2021

NICE guideline In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: 16 December 2020

Technology appraisal guidance In development

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Technology appraisal guidance In development